Compare RENT & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RENT | NTHI |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.6M | 106.0M |
| IPO Year | 2021 | 2023 |
| Metric | RENT | NTHI |
|---|---|---|
| Price | $1.81 | $2.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 187.7K | 174.8K |
| Earning Date | 09-11-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 110.16 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $329,800,000.00 | $39,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.71 | N/A |
| 52 Week Low | $1.51 | $2.50 |
| 52 Week High | $10.13 | $12.00 |
| Indicator | RENT | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 39.71 |
| Support Level | $1.51 | N/A |
| Resistance Level | $3.91 | $3.70 |
| Average True Range (ATR) | 0.14 | 0.27 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 78.95 | 23.92 |
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe to, or buy designer apparel and accessories. The company gives customers access to its unlimited closet through its subscription offering (Subscription) or the ability to rent a-la-carte through its reserve offering (Reserve). The company also gives its subscribers and customers the ability to buy its products through its Resale offering. The Closet in the Cloud offers a wide assortment of items for every occasion, from evening wear and accessories to ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear, and ski wear.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.